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Background: In acromegaly, expert surgery is curative in only about 60% of patients. 
Postoperative radiation therapy is associated with a high incidence of hypopituitarism and its 
effect on growth hormone (GH) production is slow, so that adjuvant medical treatment becomes 
of importance in the management of many patients.
Objective: To delineate the role of lanreotide in the treatment of acromegaly.
Methods: Search of Medline, Embase, and Web of Science databases for clinical studies of 
lanreotide in acromegaly.
Results: Treatment with lanreotide slow release and lanreotide Autogel® normalized GH and 
insulin-like growth factor-I (IGF-I) concentrations in about 50% of patients. The efﬁ  cacy of 
120 mg lanreotide Autogel® on GH and IGF-I levels was comparable with that of 20 mg octreotide 
LAR. There were no differences in improvement of cardiac function, decrease in pancreatic 
β-cell function, or occurrence of side effects, including cholelithiasis, between octreotide LAR 
and lanreotide Autogel®. When postoperative treatment with somatostatin analogs does not 
result in normalization of serum IGF-I and GH levels after noncurative surgery, pegvisomant 
alone or in combination with somatostatin analogs can control these levels in a substantial 
number of patients.
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Introduction
Growth hormone (GH), a polypeptide consisting of 191 amino acids and which is 
secreted by the pituitary gland, has a multitude of effects. The most obvious effect 
is the stimulation of growth in prepubertal and pubertal children. In childhood, lack 
of this hormone leads to dwarﬁ  sm and excessive secretion results in gigantism. 
Growth hormone has profound metabolic effects by stimulating protein anabolism 
and lipolysis. Other effects include stimulation of bone turnover, leading to a net 
increase in bone volume, muscle growth, insulin antagonism, renal sodium retention, 
and immuno modulation. Most of the effects of GH are indirectly mediated via 
insulin-like growth factor-I (IGF-I). IGF-I is a peptide synthesized and secreted as 
a result of GH-signaling, which acts locally in an autocrine or paracrine manner, 
or systematically as a hormone when secreted by the liver (Le Roith et al 2001). 
The liver secretes about 70% of the total circulating IGF-I in mice (Sjogren 
et al 1999).
Excessive secretion of GH leads to acromegaly, a disﬁ  guring and debilitating 
condition causing severe co-morbidity and premature death (Wright et al 1970; Ezzat 
et al 1994; Melmed 2006; Ben-Shlomo and Melmed 2008).
The purpose of this review is to establish the role of lanreotide, particularly 
lanreotide Autogel®, in the management of acromegaly based on published data. It is 
appropriate, however, to outline ﬁ  rst the clinical features of acromegaly and to discuss 
therapeutic approaches in its management.Biologics: Targets & Therapy 2008:2(3) 464
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Acromegaly
Acromegaly is a rare disease, caused by a GH-secreting 
adenoma and in even more seldom instances (about 1%) due 
to excessive GHRH secretion, usually by a carcinoid tumor 
of the lung or gastrointestinal tract (Biermasz et al 2007). 
The incidence of acromegaly is about 3–4 per 1 million 
per year and the prevalence is 60–70 per 1 million, with-
out geographical or sex differences (Alexander et al 1980 
Bengtsson et al 1988; Ritchie et al 1990; Mestron et al 2004). 
Clinical features of acromegaly include acral enlargement, 
prognatism, jaw malocclusion, arthropathy, carpal tunnel 
syndrome, hyperhydrosis, sleep apnea, and visceromegaly 
(Colao et al 2004; Melmed 2006). Acromegaly is also 
associated with increased cardiovascular morbidity and 
mortality. Active disease leads to a speciﬁ  c form of cardio-
myopathy which involves myocardium, conduction system, 
and heart valves. Clinical manifestations include arrhythmias, 
valvular regurgitation, concentric left ventricular hypertro-
phy, and left ventricular systolic and diastolic dysfunction 
(Clayton 2003; Colao et al 2004; Pereira et al 2004). The 
incidence of hypertension and of decreased glucose tolerance 
is also increased. This is also true for the incidence of colon 
polyps and colon carcinoma (Orme et al 1998; Renehan and 
Shalet 2002). It is controversial, however, whether the rela-
tive risk of cancer is increased in patients with acromegaly 
compared with that of the general population (Jenkins and 
Besser 2001; Melmed 2001; Loeper and Ezzat 2008).
Local tumoral symptoms include chronic headache, visual 
ﬁ  eld defects, and rarely cranial nerve palsies. Hypopituitarism 
is mostly associated with large tumors with a generally low 
incidence in patients with acromegaly varying from 3% to 
10 % (Greenman et al 1995).
The increased standardized mortality rate (SMR) 
decreased from 3-fold in older series to 1.3-fold in series with 
predominantly primary transsphenoidal surgery (Swaerin-
gen et al 1998; Holdaway et al 2004; Kauppinen et al 2005; 
Holdaway 2007; Dekkers et al 2008). Reported risk factors 
include diabetes mellitus, cardiomyopathy, sleep apnea, and 
cerebrovascular events and in some, but not all, studies also 
pituitary irradiation (Ayuk et al 2004; Biermasz et al 2004a; 
Kauppinen et al 2005). The decrease in mortality observed in 
acromegaly is likely to be due to the introduction of effective 
therapies such as transsphenoidal surgery in the 1970s and to 
postoperative radiotherapy, leading to normalization of GH 
and IGF-I concentrations in a substantial number of patients. 
The effective treatment of systemic co-morbidities also plays 
a role in the observed decrease in mortality. Only few patients 
using adjuvant somatostatin analogs are included in mortality 
series and it is of note that at present no mortality data exist for 
primary medical treatment including pegvisomant treatment. 
Most studies have suggested that a lower GH, for example 
below 2.5 μg/L, is associated with improved and even nor-
mal survival. In some but not all studies normal IGF-I was 
also associated with improved mortality (Ayuk et al 2004; 
Biermasz et al 2004a; Holdaway et al 2004; Kauppinen et al 
2005). Discrepancies between studies may be explained by 
a single GH or IGF-I measurement being used in most stud-
ies, which is hardly representative for disease status in the 
entire follow-up period; by the unavailability of IGF-I in a 
substantial number of patients; and by GH and IGF-I assay 
differences. In addition, individual mortality studies consist 
of relatively small numbers of patients with large conﬁ  dence 
intervals including 1.0, limiting statistical power.
In acromegaly detailed studies of spontaneous GH 
secretion have demonstrated increased pulsatility (increased 
pulse frequency), ampliﬁ  ed burst mass, and increased basal 
secretion, associated with decreased regularity (Barkan et al 
1989; Ho et al 1994; van den Berg et al 1994). Biochemical 
criteria of active disease and remission are the (mean) GH 
level, glucose-suppressed GH concentration, and the IGF-I 
level (Giustina et al 2000). GH assays differ in speciﬁ  city, 
sensitivity, and GH standard, and therefore individual clini-
cal endocrine laboratories should establish normal ranges 
of gender- and age-related GH and IGF-I values and ideally 
corrected for fat mass or a fat mass-derived parameter (Gullu 
et al 2004; Bidlingmaier and Strasburger 2007). Circulating 
IGF-I reﬂ  ects GH secretion rate and serum concentrations of 
IGF-I are elevated in all patients with active disease (Melmed 
2006). IGF-I concentrations decrease with advancing age. 
In addition, gender, sex hormone status, the use of oral 
estrogens, thyroxin, and body composition can all inﬂ  uence 
IGF-I concentrations (Clemmons 2007).
Treatment of acromegaly
As discussed above, epidemiological studies have clearly 
demonstrated that controlling GH and IGF-I secretion is the 
most signiﬁ  cant determinant of restoring survival in patients 
with acromegaly The main goal of treatment of acromegaly is 
therefore to achieve GH levels of less than 1 μg/L after a glu-
cose load, to normalize age- and gender-matched IGF-I levels, 
to ablate or reduce tumor mass and prevent its recurrence, 
and to alleviate signiﬁ  cant co-morbidities, especially cardio-
vascular, pulmonary, and metabolic disturbances (Melmed 
et al 2002). The currently available treatment modalities for 
acromegaly are selective transsphenoidal adenomectomy, 
radiotherapy, medical treatment, or combinations thereof.Biologics: Targets & Therapy 2008:2(3) 465
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Transsphenoidal surgery
This oldest treatment modality was developed a century ago 
by the Austrian neurosurgeon Schloffer (Schloffer 1907). It is 
generally performed via the transnasal, transsphenoidal route 
and is associated with low morbidity and mortality. In recent 
years most neurosurgeons have adopted the endoscope in lieu 
of the surgical microscope, which has obvious advantages for 
the patient and also leads to better visualization of the operat-
ing ﬁ  eld. Other variants of surgical techniques are neuronavi-
gating and real-time intraoperative MRI scanning, aimed at 
visualization of tiny tumor remnants after resection of the 
adenoma (Fahlbusch et al 2005; Thomale et al 2005). GH 
secretion pattern is restored when the adenoma is completely 
removed (van den Berg et al 1998). Surgical cure is highest 
in patients with a microadenoma (diameter less than 10 mm) 
varying from 80% to more than 90% in the hands of expe-
rienced neurosurgeons. However, complete tumor removal 
becomes more difﬁ  cult with increasing size of the tumor and 
expansion into the neighboring delicate structures, and the 
cure rate of large macroadenoma drops to only 20%–40% of 
cases (Freda et al 1998; Biermasz et al 2000a; Kaltsas et al 
2001; Kreutzer et al 2001; Shimon et al 2001; Beauregard 
et al 2003; De et al 2003; Nomikos et al 2005; Lüdecke and 
Abe 2006). The obvious advantage of successful surgery is 
the rapid normalization of GH secretion and decrease in IGF-
I levels, while the complication of (partial) hypopituitarism 
is generally below 10% (Nomikos et al 2005; Lüdecke and 
Abe 2006). Second surgical procedures are generally safe 
but less successful than primary surgery (Long et al 1996). 
The experience of the neurosurgeon is critical for a high cure 
rate (Ahmed et al 1999; Bates et al 2008).
Radiotherapy
Conventional radiotherapy is administered by a linear accelerator 
(4–8 MeV) with a total dose of 40–45 Gy, fractionated in at 
least 20 sessions. A rotational ﬁ  eld, 2 opposing ﬁ  elds, or a 
3-ﬁ  eld technique are used. A mean GH decrease of about 
50% is observed in the ﬁ  rst 2 years after irradiation and after 
5 years a 75% decline is reported (Biermasz et al 2000b; Wass 
et al 2003). Whether the GH level normalizes post irradiation 
mainly depends on pre-irradiation serum GH concentration and 
the time interval between radiotherapy and the measurement 
of GH and IGF-1 levels. Post-irradiation remission rates are, 
however, largely affected by the extent of surgical debulking 
prior to radiotherapy. Other than the slow onset of GH control 
another drawback is the increasing incidence of hypopituitarism 
varying from 50%–85% after a follow-up of 10 years or longer 
(Minniti et al 2005; Biermasz et al 2006).
Barkan and colleagues were the ﬁ  rst to question the 
efﬁ  cacy of radiotherapy in normalizing serum IGF-I con-
centrations, with many studies addressing the effects of 
conventional pituitary irradiation on IGF-I and strict GH 
criteria being reported thereafter (Barkan et al 1997). A few 
reports supported an apparent lack of efﬁ  cacy of pituitary 
irradiation (Thalassinos et al 1998; Cozzi et al 2001), 
whereas others reported normalization of IGF-I in 44%–79% 
of patients after 5–15 years of follow-up (Ciccarelli et al 
1993; Barrande et al 2000; Powell et al 2000; Epaminonda 
et al 2001; Minniti et al 2005).
Another radiation technique is radiosurgery, which is the 
precise, stereotactic delivery of a single high radiation dose to 
a deﬁ  ned target with a steep dose gradient at the tumor margin 
(Mahmoud Ahmed et al 2001; Castinetti et al 2005; Roberts 
et al 2007). This form of radiotherapy is performed using a 
gamma knife with up to 200 60Co sources, a Linac-based 
system, or proton beams (Marcou and Plowman 2000; Brada 
et al 2004; Sheehan et al 2005). The perceived advantage of 
this form of irradiation is that only one session is required. 
There is otherwise no convincing evidence as yet that radio-
surgery is superior to conventional irradiation in terms of 
GH control, time needed to reach clinically acceptable GH 
levels, and incidence of hypopituitarism (Landolt et al 1998; 
Attanasio et al 2003a; Biermasz et al 2006).
Disadvantages of pituitary irradiation other than 
the development of hypopituitarism include decreased 
quality of life (QoL), the development of secondary 
tumors, cerebrovascular disease, and increased mortality. 
In one cross-sectional study, decreased health-related 
QoL was described in acromegalic patients in long-
term remission (Biermasz et al 2004b). These data were 
conﬁ  rmed by another QoL analysis of treated acromegalic 
patients (Rowles et al 2005). A signiﬁ  cant predictor of 
poor QoL was radiotherapy, but the pathophysiologic 
mechanism remains unclear. Increased mortality due to 
cerebrovascular disease was observed in two of the studies 
(Ayuk et al 2004; Kauppinen et al 2005) but not in the 
other three (Bates et al 1993; Ahmed et al 1999; Biermasz 
et al 2004a).The effect of radiotherapy on mortality is 
thus as yet to be established. The likelihood of secondary 
tumor formation after pituitary irradiation is very low 
(Brada et al 1992).
Medical treatment
The three most important drugs used for medical treatment 
of acromegaly are dopamine agonists, somatostatin analogs, 
and GH-receptor modulating chemicals.Biologics: Targets & Therapy 2008:2(3) 466
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Dopamine agonists
Bromocriptine, a dopamine agonist, effectively reduces GH 
secretion in only a minority of GH-secreting adenoma (Jaffe 
and Barkan 1992). Cabergoline, a more potent dopamine 
agonist with prolonged duration of action, was reported to 
normalize GH in 35% and IGF-I in 44% of 46 patients with 
a purely GH-secreting adenoma when given at a dose of 
1–1.75 mg/week (Abs et al 1998). The efﬁ  cacy of cabergoline 
was somewhat better in tumors co-secreting prolactin. 
Quinagolide, another dopamine agonist, was reported to 
normalize IGF-I in 28% of patients (Freda 2003). Most 
endocrinologists use long-acting dopamine agonists as adjunct 
therapy in patients who fail to normalize GH secretion with 
octreotide monotherapy. The combination therapy normalizes 
serum IGF-I concentrations in 30%–40% of patients, 
irrespective of the prolactin concentration (Cozzi et al 2004). 
Side effects of cabergoline are rare although there has been 
recent concern about cardiac valve hypertrophy, as observed 
in patients with Parkinson’s disease. Whereas the dose in 
Parkinson’s disease is generally much higher than that used 
for endocrine indications (Schade et al 2007), patients with 
acromegaly generally require long-term medical treatment 
for GH control. The use of dopaminergic drugs other than 
cabergoline is probably safer in acromegaly.
Somatostatin analogs
Somatostatin was isolated in 1973 from the hypothalamus 
and subsequently synthesized (Brazeau et al 1973). The hor-
mone is processed from a large pre-prohormone into 2 cyclic 
peptides, consisting of 14 or 28 amino acids. The short form, 
SS14, is predominantly present in the brain, whereas SS28 
is widely distributed in peripheral organs. Somatostatin acts 
as neuromodulator and neurotransmitter in the brain and 
as a neurohormone in the regulation of GH and thyroid-
stimulating hormone secretion. In addition, somatostatin 
inhibits tumoral adrenocorticotropic hormone secretion in 
Cushing’s disease (van der Hoek et al 2004). Somatostatin 
acts as neurotransmitter in the extensive myo-enteric plexus, 
and as hormone in a paracrine and autocrine fashion. Via 
speciﬁ  c receptors, somatostatin exerts many inhibitory effects 
on gut and pancreatic hormones, including gastrin, insulin, 
glucagon, vasoactive intestinal peptide, motilin, and gastric 
inhibitory polypeptide. Other effects of somatostatin include 
inhibition of gastric emptying, pancreatic enzymes and bicar-
bonate secretion, gastrointestinal blood ﬂ  ow and bile ﬂ  ow 
(Brazeau et al 1973; Reichlin 1983; Patel 1999). Somatostatin 
acts via a G-protein-coupled receptor, of which 5 subtypes 
have been cloned and characterized (Lamberts et al 1996). 
After binding of somatostatin to its receptor, the activities of 
adenyl cyclase and of calcium channels are inhibited, whereas 
phosphotyrosine phosphatase activity and mitogen-activated 
protein kinases activity are stimulated. The ﬁ  rst two processes 
are involved in the inhibition of secretory processes, and the 
latter two may play a role in cell proliferation, eg, activation 
of the SST3 receptor may induce apoptosis (Danilla et al 
2001; Bevan 2005). Analogs of somatostatin differ in bind-
ing properties to different receptor subtypes (Lamberts et al 
1996). Many benign and malign tumors express one or more 
somatostatin receptors. Receptor distribution and density 
and homogeneity of receptor expression within the tumor 
determine whether a particular analog can be effectively used 
therapeutically (Krantic et al 2004; Olias et al 2004).
GH-secreting pituitary adenomas express predominantly 
SST2 and SST5 receptors. The current clinically used 
analogs, octreotide and lanreotide, inhibit GH secretion 
via the somatostatin receptor subtypes 2 and 5 (Hoﬂ  and 
and Lamberts 2003). The plasma half-life of these analogs 
is about 20 times longer than that of native somatostatin, 
which is less than 3 minutes (Lamberts et al 1996). Although 
the most important effect of somatostatin analogs is the 
inhibition of GH secretion by the adenoma leading to a 
subsequent decrease in circulating liver-derived IGF-I, part 
of the peripheral effects of these analogs is caused by the 
direct inhibition of IGF-I gene transcription after binding 
to the somatostatin receptor (Serri et al 1992; Murray et al 
2004). The magnitude of this latter effect in various organs 
is not exactly known.
GH receptor antagonists
Pegvisomant is an engineered GH analog that antagonizes 
GH at the receptor site, and thus prevents endogenous GH 
activation of its receptor and subsequent downstream sig-
naling. In short-term studies, the lowest dose (10 mg/day) 
normalized IGF-I in 38% of the patients and 20 mg normal-
ized IGF-I in 82% of patients (Trainer et al 2000; van der 
Lely et al 2001). In a minority of patients (2 out of 112 and 
7 out of 229 patients, respectively) adenoma size increased 
during a relatively short treatment period (van der Lely 
et al 2001; Schreiber et al 2007). Careful documentation of 
tumor size before starting pegvisomant treatment is therefore 
compulsory and long-term monitoring is advisable. A small 
number of patients (2 out of 167 cases) developed abnor-
malities in liver function tests, necessitating withdrawal of 
the drug, although increased liver enzyme levels, ie, more 
than 3 times the upper level of normal, was observed in 
5.5% of 229 patients, normalizing spontaneously in 3.1% Biologics: Targets & Therapy 2008:2(3) 467
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on continuing treatment (van der Lely et al 2001; Schreiber 
et al 2007). About 40% of patients develop minor abnor-
malities in liver function tests on combined treatment with 
somatostatin analogs, which do not requiring stopping of 
the drug and which usually resolve spontaneously (Feenstra 
et al 2005).
Pharmokinetics of lanreotide
The ﬁ  rst pharmaceutical available form of lanreotide (BIM 
23014) was relatively short-acting, requiring multiple dosing, 
3 times a day, or subcutaneous infusion. This was neverthe-
less a major advance in the treatment of many patients who 
had already undergone unsuccessful surgery and pituitary 
irradiation and for whom there were no other treatment 
options (Figure 1). In healthy subjects, maximal serum 
concentrations of lanreotide were reached after 30 min and 
the serum half-life was 90 min, 30 times greater than that of 
native somatostatin (Kuhn et al 1994; Antonijoan et al 2004; 
Table 1). Subsequently, a long-acting form of lanreotide was 
developed by incorporating the drug into polyactide – poly-
glycolide microspheres, so that the half-life was considerably 
prolonged, and the injection interval could be extended to 
7–14 days (Heron et al 1993). The lanreotide release pattern 
from the long-acting form is biphasic, ie, an early release 
during 2 days from the drug adsorbed onto the surface of the 
microspheres, followed by sustained release for about 1 week, 
starting at day 4, as a result of enzymatic breakdown of the 
microspheres, followed again by an exponential decrease in 
drug release. It was subsequently discovered that lanreotide 
had the unique property of self aggregation under favorable 
conditions, leading to a stable structure of highly organized 
nanotubules (Valery et al 2003, 2008). This formulation of 
the drug was named lanreotide Autogel® and has a long half-
life after subcutaneous injection determined by pseudo-ﬁ  rst 
order kinetics. Maximal serum concentrations are reached 
after 1–2 days (see Table 1) in healthy subjects and the 
serum half-life amounts to 25.5 days (Antonijoan et al 2004; 
Astruc et al 2005). In acromegalic patients maximal values 
are reached after 3.8–7.7 days under steady state conditions, 
depending on the dose administered (Table 2). Simulated 
steady state pharmacokinetic proﬁ  les of long-acting octreo-
tide and lanreotide Autogel® differ signiﬁ  cantly (Astruc et al 
2005; Bronstein et al 2005). During long-acting octreotide 
treatment, serum concentrations of the drug are more or 
less stable, whereas the characteristic ﬁ  rst-order kinetics of 
lanreotide Autogel® is superimposed on levels just before the 
next administration (see Figure 2; Astruc et al 2005). The 
pharmacokinetic differences therefore indicate that octreotide 
LAR can be better tailored to therapeutic levels, whereas 
serum levels of lanreotide must be (too) high for part of the 
interval between injections in order to be effective in the 
period before the next administration. The possible clinical 
consequence(s) of these different pharmacokinetic proﬁ  les 
can be resolved only in long-term studies in which lanreotide 
Autogel® is compared with octreotide or drugs with a similar 
pharmacokinetic proﬁ  le.
Efﬁ  cacy of lanreotide
The first studies with lanreotide were performed using 
lanreotide Slow Release (lanreotide SR). The drug was 
ﬁ  rst available in vials containing 30 mg, to be injected at 
2-weekly intervals. The interval was shortened, however, 
to 7–10 days when GH was insufﬁ  ciently suppressed. The 
drug later also became available in vials containing 60 mg 
of lanreotide so that the injection interval could be extended 
to 4 weeks, similar to that of the long established octreotide 
LAR. Studies using lanreotide SR 30 mg and lanreotide 
SR 60 mg are summarized in Table 3. Most patients had 
undergone pituitary surgery and many were irradiated, either 
as primary treatment (a minority) or as adjuvant treatment 
after noncurative surgery. In addition, in almost all studies 
patients had been treated with octreotide. Normal mean GH 
concentration, as deﬁ  ned by the authors (generally below  Figure 1 Amino acid structure of somatostatin-14, octreotide. and lanreotide.Biologics: Targets & Therapy 2008:2(3) 468
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2.5 μg/L) was achieved in 23%–93% of the cases treated 
with lanreotide SR 30 mg, and in 25%–65% of the cases 
treated with lanreotide 60 mg. Normal values of IGF-I were 
obtained in 23%–68% of patients on lanreotide SR 30 mg, 
and 35%–62% of these on lanreotide SR 60 mg. The weighted 
means of normalization of GH and of IGF-I were 54% and 
49%, respectively, during treatment with 30 mg lanreotide, 
whereas during treatment with lanreotide SR 60 mg these 
values were 60% and 58%.
Comparative studies of efﬁ  cacy between octreotide and 
lanreotide are summarized in Table 4. Short-acting octreo-
tide, mostly given 3 times a day, had a similar GH-suppres-
sive effect as lanreotide SR. Normal GH was obtained in 
52% and 49% of a total of 218 patients, but normalized IGF-I 
was more frequently found in patients treated with lanreotide 
SR 30 mg/10–14 days, ie, 49% versus 64%. The efﬁ  cacy of 
octreotide LAR was slightly higher than that of lanreotide 
SR: normalized GH and IGF-I were obtained in 64% and 
62% of 155 patients treated with octreotide LAR versus 52% 
and 50%, respectively, in the same patients during treatment 
with lanreotide SR. A limitation of all these studies, with 
one exception, is that they were not randomized. The overall 
better efﬁ  cacy of octreotide LAR compared with lanreotide 
SR agrees with ﬁ  ndings from a recent meta-analysis (Freda 
et al 2005).
Lanreotide Autogel® was introduced about 8 years ago, 
and the ﬁ  rst report in the English literature was published in 
2002. Clinical efﬁ  cacy studies are summarized in Table 5. 
Most of the patients who took part in these studies had 
undergone pituitary surgery, often with adjuvant irradiation, 
and almost all patients were on octreotide or lanreotide SR 
treatment, while a minority also used dopaminergic drugs. 
The results of these studies should therefore be considered 
critically, as a selection bias cannot be excluded. Normal GH, 
deﬁ  ned as a concentration below 2.5 μg/L in fasting single 
blood samples or as the mean of serial samples was observed 
in 38%–80% of cases and normal age-related IGF-I was 
recorded in 39%–80% of patients on lanreotide Autogel®. In 
these studies the weighted mean for GH normalization was 
58% and for IGF-I 48% in a population of 370 patients. The 
results mentioned above refer to measurements at the end 
of the study when dose titration of lanreotide Autogel® was 
fully effective. Indeed, most of the patients ended receiving 
the highest dose of 120 mg. These results do not differ from 
Table 1 Pharmacokinetic analysis of a single subcutaneous dose of short-acting lanreotide and lanreotide Autogel® in healthy subjects
Short-acting lanreotidea
n = 24
lanreotide Autogela
n = 24
lanreotide Autogelb
n = 10
lanreotide Autogelb
n = 10
Dose 7 μg/kg 60 mg 90 mg 120 mg
Cmax 7.98 ng/mL 5.71 ng/mL 6.7 ng/mL
Tmax 0.43 h 0.38 day 2.4 day 1.1 day
Half-life 1.74 h 22 days 25.5 day
AUC 16.51 ng.mL−1.h 79.48 ng.mL−1.day 116 ng.mL−1.day 133 ng.mL−1.day
MRT 1.95 h 31.97 days
aAntonijoan et al (2004); bAstruc et al (2005).
Abbreviations: AUC, area under the curve; MRT, mean residence time.
Table 2 Pharmacokinetics of lanreotide Autogel® during steady 
state conditions in patients with acromegaly
Dose  60 mg  90 mg  120 mg
Tmax (days)  85  84  85
Cmean (ng/mL)  2.46  3.04  4.52
Cmin (ng/mL)  1,82  2.51  3.76
Cmax (ng/mL)  3.82  5.69  7.69
AUC (ng.mL−1.day 68.8  85.1  127
From data of Bronstein et al (2005).
Abbreviation: AUC, area under the curve.
Figure 2 Pharmacokinetic proﬁ  les of lanreotide   Autogel® (90 mg) and octreotide-
LAR (20 mg) at steady state. The lines represent mean values of 10 simulated proﬁ  les. 
From data of Astruc et al (2005).Biologics: Targets & Therapy 2008:2(3) 469
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Lanreotide Autogel® in acromegaly
Table 6 Efﬁ  cacy of lanreotide Autogel® compared with octreotide LAR and lanreotide SR in acromegaly
Reference Duration 
(months)
Patient no 
ITT/PPP
Octreotide 
LAR dose
Lanreotide 
Autogel dose
Normal GH 
oLAR
Normal GH 
lanreotide 
Autogel
Normal IGF-I 
oLAR
Normal IGF-I 
lanreotide 
Autogel
Alexopoulou 
2004
6 25/25 20–40 mg/4 w 60/90/120 mg 64% 48% 52% 52%
Ronchi 2007 9 23/21 10–30 mg/4 w 60/90/120 mg 40% 56% 35% 39%
Andries
2008
12 12/10 10–30 mg/4 w Fixed dose 
60/90/120 mg
50% 50%a 50% 60%
anormal GH concentration 0.38 μg /L.
Abbreviations: ITT, intention-to-treat; PPP, patients per protocol; oLAR, octreotide LAR.
data obtained in patients on lanreotide SR (see above). Part 
of these studies compared the efﬁ  cacy of octreotide LAR and 
lanreotide Autogel®. A drawback of these studies is that with 
the exception of one study none were randomized (Andries 
et al 2008). An open-label, uncontrolled, single-group 
assignment study on the effects of lanreotide Autogel® in 27 
previously untreated patients with acromegaly was recently 
completed (ClinicalTrial.gov NCT00627796). Although the 
study is rather small it will contribute further data on IGF-I 
control and tumor reduction.
In a 3-month study in 107 patients, the normalization rate 
for GH was 48% during lanreotide SR and 56% during lanreo-
tide Autogel® therapy, whereas a normal IGF-I was obtained 
in respectively 45% and 48% of cases (Caron et al 2002). In 
an extension phase of this study to 12 months, normalized 
GH frequency increased from 49% to 68% in 130 patients; 
these ﬁ  gures were 44% and 50% for IGF-I (Caron et al 2004). 
Fourteen patients of these studies were treated for 3 years with 
lanreotide Autogel®. In these patients the frequency of normal 
GH increased from 36% to 77% and that for IGF-I from 36% 
to 54% (Caron et al 2006). Finally, the Spanish multicenter 
study extended the Autogel® injection interval to 8 weeks in 
patients who were controlled by 2-weekly injections with 
lanreotide SR. The overall GH control increased from 46% 
to 54% (Lucas et al 2006). The studies comparing the efﬁ  cacy 
between octreotide LAR and lanreotide are shown in Table 
6. Only the small study by Andries was properly designed, 
and showed equal efﬁ  cacies of both drugs in terms of nor-
malization of GH. Nevertheless, this study demonstrated a 
better GH-suppressive effect of octreotide on absolute GH 
concentrations than lanreotide. In contrast, the suppressive 
effect on IGF-I was similar. There was no difference in GH 
suppressive effect in a small study in 7 patients in whom the 
24 h GH secretion was precisely measured with a 10 min 
blood sampling protocol. (Van Thiel et al 2004). From the 
data presented above and despite limitations in design, it 
would appear that lanreotide Autogel® and octreotide LAR 
are equipotent in normalizing GH and IGF-I concentrations. 
Although patients require generally the highest lanreotide 
dose, most patients on octreotide LAR had safe GH and 
normal IGF-I levels on the 20 mg dose. For the practicing 
endocrinologist the message is that patients on octreotide LAR 
20–30 mg need 120 mg lanreotide Autogel® and somatostatin-
sensitive patients on octreotide LAR 10 mg require mostly 
90 mg of the Autogel® formulation. Lanreotide Autogel® is 
registered under the trade name Somatuline Autogel® in the 
majority of countries, as Somatuline Depot Injection® in the 
US, and as Ipstyl Autogel® in a few European countries.
Side effects
The most frequent side effects of lanreotide are diarrhea, 
abdominal pain, and nausea. These symptoms start mostly 
shortly after an injection, decrease subsequently, and tend 
to decrease in severity on continuing treatment. Table 7 lists 
the side effects mentioned in the clinical studies with the 2 
long-acting formulations of lanreotide. For the SR formula-
tion the gastrointestinal side effects were observed in 48% 
of the patients and for the Autogel® formulation in 52%. The 
most serious complication of somatostatin analogs is cho-
lelithiasis. The prevalence of somatostatin analog-induced 
gallstones varies geographically and may be inﬂ  uenced by 
dietary, environmental, and racial factors. The formation of 
gallstones involves the inhibition of gallbladder emptying 
and intestinal motility, inhibition of the secretion of pro-
kinetic peptides, including cholecystokinin, and increased 
intestinal and biliary production of deoxycholic acid, all of 
which promote the nucleation of cholesterol crystals and their 
aggregation into stones (Dowling et al 1992). We analyzed 
the occurrence of new cholelithiasis in patients who were 
already on somatostatin analog treatment, a condition thus 
not quite comparable to drug-naïve patients in terms of risk 
of developing gallstones. The incidence of new gallstones 
was 6% for lanreotide SR and 8.7% for lanreotide Autogel®. 
These ﬁ  gures are smaller than generally cited in literature, Biologics: Targets & Therapy 2008:2(3) 472
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but many patients had cholelithiasis caused by previous 
treatment.
Other side effects were local pain after injection and rarely 
(less than 1%) the development of nodules at the injection site. 
However, local inﬁ  ltration signs did not decrease the efﬁ  cacy 
of the drug. Other uncommon side effects included sinus 
bradycardia, asthenia, headache, pruritus, decreased libido, 
increased serum bilirubin, fatigue, constipation, and hair loss.
Inﬂ  uence of lanreotide Autogel® 
on clinical manifestations
Some studies have investigated speciﬁ  c aspects of lanreo-
tide action in acromegaly. These include detailed studies 
on glucose and insulin metabolism, effects on cardiac func-
tion, tumor growth, quality of life, and predictors of clinical 
response. These reports are brieﬂ  y summarized below.
Insulin and glucose homeostasis
GH is important in regulating glucose tolerance and insulin 
sensitivity. GH counteracts the effects of insulin by inhibit-
ing the phosphorylation of the insulin receptor. Moreover, 
GH also inhibits the phosphorylation of one of the proximate 
molecules of the insulin signaling cascade, insulin receptor 
substrate-1 in response to insulin (Kuhn et al 1992). In 
acromegaly, several studies have shown that increased GH 
induces insulin resistance (Kasayama et al 2000). However, 
GH also potentiates insulin release which is reﬂ  ected in the 
high prevalence of high insulin levels both at rest and after 
glucose challenge (Cerasi and Luft 1964). Indeed, many 
untreated patients exhibit decreased glucose tolerance and 
more detailed studies have shown reduced insulin-stimulated 
glucose disposal in muscle and impaired non-oxidative 
glucose metabolism (Sonksen et al 1967; Wass et al 1980; 
Hansen et al 1986; Foss et al 1991; Koop et al 1994). Effects 
of somatostatin analogs on glucose homeostasis are the 
resultant of delayed intestinal absorption of carbohydrates, 
inhibition of insulin release and increased insulin sensitiv-
ity via diminished GH secretion. Results from studies with 
lanreotide do not differ essentially from earlier data obtained 
with octreotide. The acute effects of subcutaneously infused 
lanreotide were studied in healthy subjects. Oral glucose 
tolerance worsened during the ﬁ  rst day of administration, but 
was restored on day 7 while drug administration continued 
(Kuhn et al 1992). In a study in 27 patients the homeostasis 
Table 7 Side effects during treatment with lanreotide SR and lanreotide Autogel® in acromegaly
Author Number 
of patients
Number 
of naive patients
Current 
treatment
GI side effects New 
cholelithiasis
Fasting glucose Tumor size 
decrease
Heron 1993 14 0 LSR 30 mg 9 2 nc
Morange 1994 19 0 LSR 30 mg 3 2 nc
Johnson 1994 8 3 LSR 30 mg 5 1 nd nd
Marek 1994 13 0 LSR 30 mg 13 1 nc 5/13 (20%)
Giusti 1996 57 0 LSR 30 mg 22 2 nc
al-Maskiri 1996 10 0 LSR 30 mg 10 1 nc
Caron 1997 22 0 LSR 30 mg 13 4 nc
Suliman 1999 30 7 LSR 30 mg 26 2 nc 1/7
Colao 1999 45 0 LSR 30 mg 12 1 nm
Chanson 2000a 58 0 LSR 30 mg 40 6 nc
Baldelli 2000 118 23a LSR 30 mg 64 4 nm. 5/23 (20%)
Cozzi 2000 21 8 LSR 60 mg nd 0 nc 5/13
Cannavo 2000 22 0 LSR 30 mg few 2 nm.
Verhelst 2000 66 3 LSR 30 mg 41 2 nc
Ambrosio 2002 20 0 LSR 60 mg 10 0 nc 0/4
Attanasio 2003b 92 22 LSR 60 mg 8 10 nc 11/22
Caron 2004 130 0 LAUT 58 12 nd
Ashwell 2004 12 0 LAUT 0 nd nd
Alexopoulou 2004 25 0 LAUT 8 0 nc
Ronchi 2007 23 0 LAUT nd 1 nc
Chanson 2008 63 nd LAUT 53 8 increase in 4
Decrease of tumor size is given only for patients who had no previous radiotherapy or somatostatin analog treatment. aSix patients had been treated with bromocriptin.
Abbreviations: nd, no data available; nc, no signiﬁ  cant change of glucose concentrations; nm, not mentioned; LSR, lanreotide slow release; LAUT, lanreotide Autogel.Biologics: Targets & Therapy 2008:2(3) 473
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model assessment (HOMA) index improved, but not the 
quantitative insulin check index (QUICKI) index (Ronchi 
et al 2003). In a cross-sectional study with 51 acromegalic 
patients of whom 18 were on lanreotide Autogel® the pan-
creatic β-cell function deteriorated but insulin resistance 
remained unchanged (Stefﬁ  n et al 2006). The most precise 
study used the euglycemic hyperinsulinemic clamp. Twenty-
four patients were studied at baseline and after 6 months 
treatment with either octreotide LAR or with lanreotide SR. 
Hemoglobin A1c (HbA1c) increased signiﬁ  cantly. In patients 
with a normal glucose tolerance at baseline the glucose con-
centration at 120 min increased, together with decreased and 
delayed insulin response. Insulin sensitivity increased in all 
12 clamped patients. The investigators could not demonstrate 
differences between octreotide and lanreotide, ie, the effects 
on GH, IGF-I, and insulin were all similar (Baldelli et al 
2003). The effects of other pharmacologic therapies currently 
used for the treatment of acromegaly on glucose metabolism 
and insulin resistance were recently reviewed (Pereira et al 
2005). In most studies, not speciﬁ  cally focused on insulin and 
glucose metabolism, fasting glucose concentrations and/or 
HbA1c levels did not change signiﬁ  cantly when the GH-
suppressive medication was changed to lanreotide or when 
the period of lanreotide administration was compared with 
the period without GH-suppressive medication.
Cardiac effects
Acromegaly is associated with increased cardiac morbidity 
and mortality. Recognized cardiac manifestations include 
chronic cardiac failure due to systolic dysfunction (cardiomy-
opathy) or isolated diastolic dysfunction (Colao et al 2004; 
Pereira et al 2004). In addition, our group documented the 
increased prevalence of regurgitant valvular heart disease 
in acromegaly (Pereira et al 2004). An important ques-
tion is whether effective GH-suppressive medication can 
improve cardiac function. One of the ﬁ  rst studies reported 
on 13 patients treated with lanreotide. In this study there was 
a parallel decrease in GH and IGF-I and in left ventricular 
mass index; these data were conﬁ  rmed in another study 
(Baldelli et al 1999; Hradec et al 1999). Octreotide was used 
in most studies on cardiac function, because this drug was 
the earliest available for clinical studies (Maison et al 2007).
These studies indicate that effective GH-suppressive medica-
tion improves morphological and functional hemodynamic 
parameters, although medical therapy does not normalize 
all parameters. These observations concur with results of 
another study, which compared outcome in long-term surgi-
cally cured patients with medically controlled patients and 
which showed better results in the ﬁ  rst group (van Thiel et al 
2005), suggesting that GH-suppressive therapy in its pres-
ent form is unable to fully correct cardiac dysfunction. The 
impact of this ﬁ  nding on long-term mortality in acromegaly 
is unknown.
Tumor growth
The anti-tumoral effects of somatostatin analogs are linked 
to the activation of the subtype receptors SSTR1, SSRT2, 
SSTR4, and SSTR5, which all induce cell cycle arrest. Apop-
tosis is associated with SSTR3 and possibly also with SSTR2 
signaling (Danilla et al 2001; Bevan 2005). GH secreting ade-
nomas express different somatostatin receptors, as shown for 
example by a recent study in which 77% expressed SSTR2, 
69% SSTR1 and SSTR3, and 60% SSTR5. In the same study, 
lanreotide inhibited cell proliferation in vitro in 10 out of 
13 adenomas (Florio et al 2003). Lanreotide also stimulates 
apoptosis as was found in surgically removed GH secreting 
adenomas to 8.7 ± 2.6% in tumors compared with less than 
3.5 % in controls (Wasko et al 2003). The clinical response in 
terms of GH control and tumor size reduction correlates with 
the expression of somatostatin receptor subtype 2a (Fougner 
et al 2008; Taboada et al 2008) Preoperative treatment with 
lanreotide SR for 1–3 months in 104 acromegalic patients 
led to tumor size reduction in 66%, with a mean decrease of 
152 mm3. A decrease in adenoma size of more than 20% was 
found in 29% of the patients (Lucas et al 2003). Other studies 
in which the decrease in adenoma size could be evaluated are 
listed in Table 7. In the meta-analysis of 14 clinical studies 
using somatostatin analogs as primary treatment, 36.6% of 
the patients exhibited a signiﬁ  cant reduction in tumor size, 
with a weighted mean of 19.4% (Melmed et al 2005). Factors 
(not necessarily predictors) associated with tumor shrinkage 
after primary therapy with somatostatin analogs were post-
treatment IGF-I, the age of the patient and the percentage 
GH decrease (Colao et al 2006a), and essentially conﬁ  rming 
previously reported ﬁ  ndings (Lucas et al 2003). In another 
meta-analysis of 44 trials, tumor shrinkage was related to the 
choice of the somatostatin analog. Octreotide LAR appeared 
to be more potent than lanreotide SR, with an odds ratio of 9.4 
(Freda et al 2005). Preliminary data on biochemical remission 
of acromegaly after somatostatin analogs withdrawal suggest 
that some well-responsive patients might be cured, but long-
term follow up is clearly needed (Ronchi et al 2008).
Quality of life
QoL remains impaired in acromegaly even after successful 
pituitary surgery due to persisting joint-related complaints Biologics: Targets & Therapy 2008:2(3) 474
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(Biermasz et al 2005a). An early open study on the effect 
of lanreotide SR on QoL suggested a positive effect of 
treatment (Sonino et al 1999). However, in another study 
comprising 52 acromegalic patients no differences could 
be shown between lanreotide-controlled and noncontrolled 
patients using the AcroQoL, a questionnaire speciﬁ  cally 
developed for acromegaly. Interestingly, in the controlled 
group, surgically cured patients were much better off than 
patients controlled with lanreotide (Hua et al 2006). This 
observation underscores subtle differences between resto-
ration of normal physiology and effective GH-suppressive 
medication, as found in intensive GH sampling studies in 
acromegalic cohorts (Biermasz et al 2004c). Finally, in a 
study of 93 patients with acromegaly control of GH and IGF-I 
had a positive impact on the subscale appearance, but overall 
QoL was severely impaired (Matta et al 2008).
Predictors of clinical response
A priori conditions for a favorable clinical response to 
somatostatin analog therapy are the density and distribution 
of SSTR2a receptors in the adenoma (Lamberts et al 1996). 
It is controversial whether a single acute octreotide test can 
predict the clinical response during long-term treatment. In 
this respect 3 studies reported positive results (Biermasz et al 
2005b; Gilbert et al 2005; Karavitaki et al 2005), whereas 
3 others concluded that the test was not useful (Colao et al 
1996; de Herder et al 2005; Prokajac et al 2005). The absolute 
height of pretreatment GH levels is obviously another impor-
tant factor for the efﬁ  cacy of treatment, and indeed several 
studies have demonstrated that tumor debulking procedures 
improved the clinical outcome of medical therapy (Colao 
et al 2006b; Karavitaki et al 2007).
Primary pharmacologic treatment
Patients with a high chance of curative surgery should be 
offered this treatment. However, primary medical treat-
ment should be considered in patients with a high surgical 
risk, patients with large invasive tumors and obviously in 
those who refuse surgery. Dose escalation with short-acting 
octreotide resulted in a better outcome in patients treated with 
octreotide as primary medication than those who received 
this drug as adjuvant medication after surgery (Newman 
et al 1995). Given as primary treatment, octreotide LAR 
controlled GH secretion in 57%, IGF-I in 45%, and caused 
tumor reduction of more than 50% in 44% out of 99 patients 
(Colao et al 2006a). This group and Cozzi and colleagues 
also found that dose escalating resulted in an even better 
outcome (Cozzi et al 2003; Colao et al 2007). Limitations 
of these studies are that they are not randomized to primary 
surgery and that no data are available on long-term effects 
on survival.
Primary medical treatment may also be aimed at improve-
ment of surgical outcome. Most of the studies addressing 
this issue had an open label design. Three studies reported 
beneﬁ  cial effect on outcome (Barkan et al 1988; Colao et al 
1997; Stevenaert and Beckers 1996), whereas three others 
did not (Biermasz et al 1999; Kristof et al 1999; Abe and 
Lüdecke 2001). Therefore, a conclusive statement cannot be 
made on this issue.
Failures of medical therapy
As outlined above, somatostatin analog treatment will not 
control clinical symptoms and biochemical parameters in all 
acromegalic patients, and about half of them will still have 
raised IGF-I and/or GH levels. An increase in the injection 
frequency of lanreotide Autogel® to once every 2–3 weeks is 
generally not successful (Abrams et al 2007). Another, less 
expensive approach is to combine treatment with dopaminer-
gic agonists (Freda 2003; Cozzi et al 2004). More effective 
is combined treatment with pegvisomant as demonstrated 
by a single center open labeled study. Long-term efﬁ  cacy of 
combined treatment was demonstrated in 32 patients who all 
normalized IGF-I with pegvisomant in a dose of 40–160 mg 
given once weekly (24 patients) or twice weekly (Neggers 
et al 2007). Two large multicenter studies are respectively 
ongoing and complete, in which weekly administered pegvi-
somant is combined with lanreotide Autogel® in patients 
not controlled during treatment with 120 mg lanreotide 
Autogel® (ClinicalTrials.gov, NCT 00383708) and daily 
pegvisomant injections with ocreotide LAR (ClinicalTrials.
gov, NCT 0068029). Preliminary results of the latter study 
suggest equal efﬁ  cacy in the two randomized parallel treat-
ment groups towards serum IGF-I normalization, but with 
a higher incidence of side effects in the combined treatment 
group (Harris et al 2007). Considering the number of patients 
included, these studies will most likely answer questions 
about the efﬁ  cacy of combined somatostatin analog and GH-
receptor blockage in the treatment of acromegaly. However, 
both studies did not exclude previous surgery or radiation 
therapy, so that any conclusions drawn from these studies 
may not be applicable to primary medical treatment.
Due the favorable receptor binding proﬁ  le, SOM230 
(pasireotide) is likely to be a powerful somatostatin ana-
log, which might be used in therapy-resistant cases to the 
registered somatostatin analogs (van der Hoek et al 2005; 
Ben-Shlomo and Melmed 2007). Clinical Phase II studies Biologics: Targets & Therapy 2008:2(3) 475
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in acromegaly are now being carried out in the US with 
both the short-acting form as well as the slow-release for-
mulation (ClinTrial.gov NCT000088582, NCT00171730, 
and NCT00600886). Other somatostatin agonists currently 
developed were recently reviewed (Roelfsema et al 2006). 
Potential interesting drugs are chimeric somatostatin analogs. 
This class of drugs combines dopamine and somatostatin 
structural elements and retains afﬁ  nity for speciﬁ  c somatosta-
tin and dopamine receptor subtypes. These new drugs can 
not only suppress GH (and other pituitary hormones) better 
than currently clinically used drugs, but may also have much 
stronger antiproliferative actions, at least in vitro (Ferone 
et al 2007; Zatelli et al 2007).
Summary and future perspectives
Lanreotide Autogel® is an exceptional pharmaceuti-
cal achievement, based on the unique property of self-
aggregation of lanreotide. The formulation is delivered in 
preﬁ  lled syringes and can be easily injected without medical 
supervision by the patient or partner after proper training 
(Bevan et al 2008), whereas octreotide LAR requires quali-
ﬁ  ed personnel for administration.
Lanreotide SR 30 mg/7–14 days can control serum GH in 
59% and IGF-I concentrations in 49% of patients, while the 
results of the 60 mg formulation/4 weeks are 60% and 58%, 
respectively. Lanreotide Autogel® controls GH in 58% and 
IGF-I in 48% of patients. Compared with octreotide LAR the 
efﬁ  cacy of lanreotide SR is less, although the differences are 
not large (Freda et al 2005). No large scale data are available 
for lanreotide Autogel®, a latecomer in this therapeutic ﬁ  eld, 
for making a reasonable comparison with octreotide LAR.
The present formulations of somatostatin analogs 
can be classiﬁ  ed as a second generation of effective GH-
suppressive drugs, but these agents are clearly not adequate 
for all patients, depending on tumor somatostatin receptor 
status. New somatostatin analogs include SOM230, which 
is currently being used in several trials in the US, and the 
potentially very powerful chimeric drugs developed by Ipsen 
SA. The latter drugs, if successful in phase II–IV studies, will 
probably take another 5–10 years before becoming available 
for clinical use by endocrinologists. At present patients not 
controlled by somatostatin analogs should be treated with 
adjuvant pegvisomant, either as daily injections, as recom-
mended by Pﬁ  zer, or as once-weekly or 2-weekly injections 
in a titrated dose, which data in the literature have suggested 
as sufﬁ  cient (Feenstra et al 2005; Jørgensen et al 2005; 
Harris et al 2007; Neggers et al 2007). It is to be expected 
that other GH receptor blocking agents will become available 
in the future, which might not have the potential drawbacks 
of pegvisomant (Roelfsema et al 2006).
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